The AllCells Blog

AllCells Blog

AllCells blog posts are dedicated to highlighting scientific trends, innovation, and technological advances within the biomedical industry. Data-driven studies and primary research are conducted to create our blogs and include experts within the following fields: immuno-oncologists, cell and gene therapy, academia, government, and contract research organizations.

Better Together: Discovery Life Sciences and AllCells Join Forces

January 30, 2023

In July of 2022, AllCells was acquired by Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists™. By combining over 30 years of cell and gene therapy (CGT) expertise, our […]

How AllCells’ Expanded Donor Collection Facilities Help You to Recruit the Right Donors and Scale Your Cell and Gene Therapy Development

November 7, 2022

Unlike classical therapeutics (i.e., monoclonal antibodies), the raw starting materials for cell and gene therapies (CGTs) are derived from patient or donor cells. As such, these sources are not mass-produced […]

The Key to Developing Good Manufacturing Practice (GMP) Biomaterials for Cell and Gene Therapy Development

October 3, 2022

A decade ago, the emergence of new immunotherapies in the cell and gene therapy (CGT) space opened up new avenues to treat disease, sparking excitement across the industry. However, the […]

Overcoming the Global Biomaterial Supply Chain Challenge for the Development of CAR-T Therapies

September 21, 2022

By 2026, commercial chimeric antigen receptor (CAR)-T cell therapies are on track to make up the largest share of oncology drug sales for pediatric and young adult patients1. This is […]

Dual Mobilization Enhances CD34+ Yield Across All Donor Types

August 1, 2022

Mobilized peripheral blood has now surpassed bone marrow as the preferred source of CD34+ hematopoietic stem and progenitor cells (HSPCs) for allogeneic hematologic transplantation and translational medicines because both the […]

The Therapeutic Potential of HSC-based Gene Therapies

July 25, 2022

Hematopoietic stem cells (HSCs) have immense therapeutic potential because of their ability for both self-renewal and multi-lineage differentiation to maintain hematopoietic homeostasis. This rare population of cells are characterized by […]

A Decade of Innovation: CAR-T Successes and Latest Developments

July 6, 2022

After a decade of innovation, chimeric antigen receptor (CAR)-T cell therapy remains at the forefront of the cell and gene therapy space, continuing to forge new ground to treat previously […]

Cell Therapy

Why You Should Start Clinical Grade Cell Supply Discussions Early in Cell and Gene Therapy Development

May 24, 2022

Cell and gene therapies represent an expanding category of transformative medicines with the potential to change the way we treat human diseases. Broadly, these novel therapies include both in vivo […]

Dna Double Helix

What You Need to Know About Regenerative Medicine in 2022: Industry and Tech Trends

April 20, 2022

Growth in the Regenerative Medicine Field The regenerative medicine sector is on track for another watershed year where clinical progress, continued growth, and segmentation into new disease areas affecting larger […]

AllCells Opens a New Collection Facility in Houston, Texas

March 29, 2022

Expanding Its Donor Network AllCells, the leading provider of human hematological products and services, is pleased to announce the opening of a new, 3600 sq ft LeukoLab cell collection facility […]

Subscribe to Our Blog

Stay current with the AllCells Blog. Get email updates with helpful resources for biomedical researchers:

Customer Service

How Can We Help You?


Looking for research tips? Need help sourcing materials? How about a few more articles on therapies or processes? At AllCells, we believe that partnerships create the best pathways to success. Our Customer Success Team has years of industry experience and a wealth of resources to help you get the most out of your cellular products. We’re only a few clicks away.

Contact Us
Have a question? Let’s chat.